Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 89Daunorubicin 45Azacitidine 43Idarubicin 27venetoclax 26fludarabine 26Etoposide 25Cyclophosphamide 25Mitoxantrone 22Decitabine 19Busulfan 19Methotrexate 16Gemtuzumab 14Granulocyte Colony-Stimulating Factor 12Whole-Body Irradiation 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10gilteritinib 9Filgrastim 9fludarabine phosphate 8Tacrolimus 8Mycophenolic Acid 8Cyclosporine 8Tretinoin 7Radiotherapy 7Drug Therapy 7Observation 6Homoharringtonine 6Antilymphocyte Serum 6quizartinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myeloid, Acute × flt3 ligand protein × Clear all
NCT00006223 2013-06-24

flt3L in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡